Octozi, founded by Amit Patel, Cedric Odje, and Matthew Purri in 2023, raised $3 million in seed funding led by Surface Ventures with participation from Remarkable Ventures, to build an AI platform that automates clinical trial data cleaning and review for pharmaceutical companies.
The company targets one of the most tedious and error-prone parts of drug development: the manual process of reviewing and cleaning clinical trial data before it can be submitted to regulators or used for analysis. Data quality issues in clinical trials can delay drug approvals by months, making the underlying workflow a genuine bottleneck for pharmaceutical companies rather than a minor administrative task.
The round is a modest one by 2026's headline standards, but fits a consistent and recurring theme across this year's funding data: AI applied to narrow, high-stakes, compliance-heavy workflows in regulated industries, where the cost of manual error is high enough that companies are willing to pay for automation even at an early product stage.
For founders building AI tools for pharma, biotech, or other heavily regulated industries, Octozi's raise reinforces a pattern seen throughout 2026: investors continue to back founders who pick one specific, painful, well-understood workflow inside a regulated industry rather than positioning broadly as an AI platform for healthcare or life sciences.